CA
INKT icon

Clearstead Advisors’s MiNK Therapeutics INKT Stock Holding History

Clearstead Advisors’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164 Hold
14
– – ﹤0.01% 3254
2026
Q1 		$148 Hold
14
– – ﹤0.01% 2184
2025
Q4 		$157 Hold
14
– – ﹤0.01% 2451
2025
Q3 		$196 Hold
14
– – ﹤0.01% 2865
2025
Q2 		$104 Hold
14
– – ﹤0.01% 2617
2025
Q1 		$121 Buy
+14
New +$125 ﹤0.01% 2140
2024
Q4 		– Sell
-15
Closed -$110 – 2138
2024
Q3 		$110 Hold
15
– – ﹤0.01% 1994
2024
Q2 		$143 Buy
+15
New +$146 ﹤0.01% 1980

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Clearstead Advisors's INKT Position: Q2 2026 in Review

Clearstead Advisors held its MiNK Therapeutics (INKT) position steady in Q2 2026 at 14 shares worth $164. The position accounts for ﹤0.01% of the portfolio, ranked #3254.

Clearstead Advisors first reported a position in INKT in Q2 2024 and has held it in 8 quarters since. The position peaked at $196 in Q3 2025. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Clearstead Advisors held 14 shares of MiNK Therapeutics worth $164 as of Q2 2026.
  • Clearstead Advisors left its MiNK Therapeutics share count unchanged in Q2 2026.
  • MiNK Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3254 holding.
  • Clearstead Advisors first reported a position in MiNK Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Clearstead Advisors's MiNK Therapeutics position peaked at $196 in Q3 2025.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.